American Cures Act
Summary
The American Cures Act authorizes and appropriates approximately $891B over 10 years for NIH and CDC biomedical research, with automatic CPI adjustments and exemptions from sequestration and PAYGO. This permanent funding commitment directly benefits life sciences tools companies ($TMO, $DHR) and clinical research organizations ($IQV, $ICLR, $ILMN) by guaranteeing a sustained increase in federal research spending.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The American Cures Act locks in ~$891B in mandatory-like biomedical research funding over 10 years, growing with CPI.
- 2.Life sciences tools companies ($TMO, $DHR) are the direct beneficiaries, as NIH grants fund equipment and consumables purchases.
- 3.CROs ($IQV, $ICLR) and sequencing leader ($ILMN) also benefit from expanded research pipelines and genomic studies.
- 4.The bill is early-stage and faces partisan hurdles, but its permanent funding structure makes it a long-term tailwind if enacted.
Market Implications
The American Cures Act provides a long-term demand signal for the life sciences tools and clinical research sectors. $TMO and $DHR, as market leaders in lab supplies, are positioned to capture a significant share of the incremental spending. $IQV and $ICLR benefit from expanded clinical trial activity. $ILMN gains from genomic research growth. Without real market data, specific price levels cannot be cited, but the structural revenue uplift is estimable. The bill's likelihood of passage in the 119th Congress is modest given divided control, but the bipartisan appeal of biomedical research funding could facilitate inclusion in must-pass legislation.
Full Analysis
-
What happened and current status: On May 12, 2026, Senator Durbin (D-IL) introduced S.4494, the American Cures Act, which was read twice and referred to the Senate Committee on Appropriations. The bill is in early legislative stage; four Democratic cosponsors have signed on. No companion bill has been introduced in the House.
-
The money trail: This bill is unusual because it both authorizes AND appropriates funding—it explicitly states 'there are hereby authorized to be appropriated, and appropriated' for NIH, CDC, DoD health program, and VA medical research. For NIH, FY2027 starts at $52.5B and escalates annually by CPI through FY2037 and beyond; CDC starts at $9.9B with similar escalations. Sum of specified NIH and CDC amounts for FY2027-2036 totals ~$891B. The bill exempts these funds from sequestration and both statutory and Senate PAYGO rules, making the spending mandatory-like. Note: The DoD health program and VA research amounts are also authorized but only partial figures are shown in the text.
-
Convergence: No related signals or procurements are provided in the enrichment data, so this bill is analyzed as a standalone legislative event.
-
Structural winners: The clear beneficiaries are companies supplying the infrastructure of biomedical research. Thermo Fisher ($TMO) and Danaher ($DHR) are the dominant players in lab equipment and consumables, with NIH-funded researchers as a core customer base. Clinical research organizations IQVIA ($IQV) and ICON ($ICLR) will see increased demand as NIH-funded basic research translates into more clinical trials. Illumina ($ILMN) is the leading genomic sequencing provider, and increased NIH genomics funding directly drives instrument and consumable sales. All these companies have high exposure to federal research funding streams.
-
Timeline and legislative steps: The bill is at the earliest stage—referred to committee. It must pass the Senate and House, then be signed by the President. Given the large fiscal commitment and partisan sponsorship (all Democrats), passage is uncertain in the current divided 119th Congress. The next key step is a committee hearing and markup in Appropriations. Progress will depend on budget negotiations and potential inclusion in omnibus spending bills.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Bill appropriates $52.5B for NIH in FY2027 with annual CPI-adjusted increases through FY2037 and beyond, funding research grants, equipment, and consumables.
Who must act
NIH-funded academic medical centers, universities, and research institutes
What happens
Increased demand for lab equipment, reagents, and consumables from NIH-funded researchers, estimated 3-5% incremental revenue growth in the life sciences tools market.
Stock impact
Thermo Fisher's Life Sciences Solutions and Fisher Scientific segments capture ~30% market share in lab supplies; incremental NIH funding directly boosts sales of mass specs, sequencers, chemicals, and plasticware. Estimated $500M-$1.5B additional annual revenue at peak funding levels.
What the bill does
Same NIH funding mechanism drives procurement of bioprocess equipment, diagnostics, and lab automation.
Who must act
NIH-funded research institutions
What happens
Higher spending on bioprocess chromatography, cell culture, and analytical instruments used in biomedical research.
Stock impact
Danaher's Life Sciences segment (Cytiva, Beckman Coulter, Sciex) sees increased instrument and consumable orders; estimated $300M-$1B in additional annual revenue.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Carla Walker Act
A bill to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes.
To require the Secretary of Energy to establish a centralized resource for access to data to facilitate biological research through enabling advanced computational methods such as artificial intelligence, and for other purposes.
AI-Ready Bio-Data Standards Act
Cloud LAB Act of 2026
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.0B Department of Health and Human Services Grant
DEPARTMENT OF SOCIAL SERVICES CONNECTICUT: $6.9B Department of Health and Human Services Grant
STATE OF COLORADO - DEPT OF HEALTH CARE POLICY & FINANCING: $9.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →